2.1 Radiation Safety

Sodium Iodide I 131 Capsules Diagnostic is a radioactive drug and should be handled with appropriate safety measures to minimize radiation exposure to the patient and healthcare worker [see Warnings and Precautions (5.2)].

• Use waterproof gloves during the entire handling and administration procedure.
• Maintain adequate shielding during the life of the product.
• Open the capsule-containing vial in a well ventilated hood to avoid exposure to trace levels of volatile I-131 which may be present.
• Measure patient dose by a suitable radioactivity calibration system immediately prior to administration.

2.2 Recommended Dosage and Administration Instructions

Administer Sodium Iodide I 131 Capsules Diagnostic orally prior to scanning. The recommended dose of Sodium Iodide I 131 Capsules Diagnostic for an adult patient is the following:

• Thyroid Function: 0.185 to 1.1 megabecquerels (MBq) [5 to 30 microcuries (microCi)]. Administer 24 hours before uptake measurement.
• Thyroid Imaging (Scintigraphy): 1.85 to 3.70 MBq (50 to 100 microCi). Administer 16 -24 hours before imaging.

Consult the color-coded decay calendar that is updated in January of every year to determine which colored capsule(s) correspond to the prescribed dose: https://www.draximage.com/products/us/draximage-i-131-diagnostic-capsules/ or calculate the correct dose from the date and time of calibration provided on the container label.

Prior to Sodium Iodide I 131 Capsules Diagnostic Administration

• Obtain a pregnacy test in females of reproductive potential prior to administration to verify the absence of pregnancy [see Contraindications (4) and Use in Specific Populations (8.1, 8.3)].
• Advise patients to maintain a low-iodine diet two weeks prior to radioiodine administration and continue for several days during the uptake or imaging process [see Drug Interactions (7)].
• Advise patients to fast at least 2 hours before and 2 hours after administration to ensure absorption.
• Advise patients to hydrate before and after administration of radioiodine and void frequently to ensure rapid excretion.

2.3 Radiation Dosimetry

The biokinetic and radiation dose distributions associated with thyroid uptake of iodide I 131 depend on dietary intake of stable iodine. A range of uptake percentages in an average adult (73.7 kg) are shown in Table 1. For a thyroid blocked from iodide uptake in the production of hormones, the effective half-life of iodide I 131 is approximately 1.4 hours; for "low" to "high" uptake, the effective half-life of I 131 ranges from approximately 80 to 90 hours.

5.1 Fetal Toxicity

Sodium Iodide I 131 Capsules Diagnostic is contraindicated in pregnancy because sodium iodide I 131 crosses the placenta and can cause severe and irreversible hypothyroidism in the neonate. Multiple reports in the literature describe neonatal hypothryroidism following in utero exposure to sodium iodide I 131. Some of these cases were severe and irreversible. Verify pregnancy status of females of reproductive potential prior to administering Sodium Iodide I 131 Capsules Diagnostic [see Use in Specific Populations (8.1, 8.3)].

5.2 Radiation Exposure

Sodium Iodide I 131 Capsules Diagnostic contributes to a patient’s overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Follow safe administration instructions to minimize radiation exposure to the patient and healthcare providers [see Dosage and Administration (2.1)].

5.3 Risk of Radioactive Uptake Measurement and Imaging Misinterpretation

The recent intake of stable iodine in any form, or the use of thyroid or anti-thyroid drugs will affect the uptake of sodium iodide I 131. Question the patient carefully regarding their exposure to these drugs or procedures involving radiographic contrast media [see Drug Interactions (7)].

5.4 Hypersensitivity Reactions

Hypersensitivity reactions including anaphylaxis may occur in patients who receive sodium iodide I 131. Although iodine is not considered an allergen, hypersensitivity reactions may occur in relation with excipients or chemical component of the capsule, such as sodium thiosulfate. Obtain and document an allergy history, particularly a sulfite allergy. Emergency resuscitation equipment and personnel should be immediately available [see Adverse Reactions (6)].

8.1 Pregnancy

Risk Summary

Sodium Iodide I 131 Capsules Diagnostic is contraindicated in pregnancy because fetal exposure can lead to neonatal hypothyroidism, which in some cases is severe and irreversible. Data from the published literature describe reports of neonatal thyroid abnormalities after fetal exposure, including agenesis of the thyroid and hypothyroidism (see Clinical Considerations, Data). No animal reproductive studies have been conducted.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2-4% and 15-20%, respectively.

Clinical Considerations

Fetal/Neonatal Adverse Reactions

A fetus exposed to sodium iodide I 131 can develop neonatal hypothyroidism. Delay in diagnosis of neonatal hypothyroidism after exposure to sodium iodide I 131 in utero can result in severe sequelae such as decreased mental capacity and delayed skeletal maturation. Monitor thyroid function in any infant born after in utero exposure to sodium iodide I 131.

Data

Human Data

Literature reports of maternal exposures to sodium iodide I 131 at doses of 330-8300 MBq during 4-26 weeks estimated gestational age. There were various adverse pregnancy outcomes; the most common was hypothyroidism in infants and children.

8.2 Lactation

Risk Summary
Advise women to discontinue breastfeeding after administration of Sodium Iodide I 131 Capsules Diagnostic. Infant exposure to sodium iodide I 131 via breast milk is expected and may lead to hypothyroidism in the infant because sodium iodide I 131 in breast milk may reach concentrations equal to or greater than concentrations in maternal plasma (see Data).

Data
Published studies show that sodium iodide I 131 is transferred into breast milk and is taken up by the thyroid of the breastfed infant.

8.3 Females and Males of Reproductive Potential

Sodium Iodide I 131 is contraindicated in pregnancy because it causes fetal hypothyroidism [see Use in Specific Populations (8.1) and Warnings and Precautions (5.1)].

Pregnancy Testing
Obtain a pregnancy test in females of reproductive potential and verify the absence of pregnancy before administering Sodium Iodide I 131 Capsules Diagnostic [see Dosage and Administration (2.2)].

8.4 Pediatric use

Safety and efficacy in pediatric patients have not been established. Published reports suggest that the thyroid gland of pediatric patients is more sensitive to the adverse effects of sodium iodide I 131 (e.g., increased risk of radiation absorption).

8.5 Geriatric Use

Clinical experience has not identified differences in safety or effectiveness in geriatric patients compared to younger patients. However, elderly patients are more likely to have decreased renal function and radiation exposure is greater in patients with impaired renal function [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].

8.6 Renal Impairment

Radiation exposure following Sodium Iodide I 131 Capsules Diagnostic is greater in patients with impaired renal function compared to patients with normal renal function [see Clinical Pharmacology (12.3)].

11.1 Chemical Characteristics

Sodium Iodide I 131 Capsules Diagnostic is a radiodioactive diagnostic agent containing sodium iodide I 131 and supplied for oral administration in a gelatin capsule. Each capsule contains no-carrier-added sodium iodide I 131, disodium edetate dihydrate USP as a stabilizer, sodium thiosulfate pentahydrate USP as a reducing agent, and dibasic sodium phosphate anhydrous USP.

Sodium Iodide I 131 is designated chemically as Na131I and has a molecular weight of 153.99.

11.2 Physical Characteristics

Iodine I 131 decays by beta emission and associated gamma emission with a physical half-life of 8.04 days. The principal radiation emissions are listed in Table 4.

11.3 External Radiation

The specific gamma-ray constant for iodine I 131 is 4.26 x 10-13 C•m2•kg-1•MBq-1•s-1 (2.2 R•cm2/mCi•hr). The first half-value thickness of lead (Pb) for iodine I 131 is 0.27 cm. A range of values for the relative attenuation of the radiation emitted by iodine I 131 that results from interposition of various thicknesses of Pb is shown in Table 5. For example, the use of 2.59 cm of Pb will decrease the external radiation exposure by a factor of about 100.

To correct for physical decay of iodine I 131, the fractions that remain at selected intervals after the time of calibration are shown in Table 6.

12.1 Mechanism of Action

Iodine is actively transported by the sodium-iodide symporter (NIS) protein, in thyroid follicular cells. Iodide is concentrated in follicular cells up to 50 times higher than in the plasma. Iodide is metabolically oxidized by thyroid peroxidase to iodinium (I+) which in turn iodinates tyrosine residues of thyroglobulin (tri or tetra-iodinated tyrosine). The gamma emission of Iodine I 131 is imaged or counted.

12.3 Pharmacokinetics

Absorption
Following oral administration of Sodium Iodide I 131 Capsules Diagnostic, 90% of the administered radioactivity of sodium iodide I 131 is systemically absorbed in the first 60 minutes.

Distribution
Following absorption, sodium iodide I 131 is distributed within the extra-cellular space. It is actively transported by the sodium-iodide symporter (NIS) protein and binds to thyroglobulin resulting in accumulation in the thyroid. The thyroid uptake of iodide is usually increased in hyperthyroidism and in goiter, and is decreased in hypothyroidism. Sodium iodide I 131 also accumulates in the stomach, choroid plexus, salivary glands breast, liver, gall bladder, and kidneys.

Elimination
Metabolism
In thyroid follicular cells, iodide is oxidized through the action of thyroid peroxidase to iodinium (I+) which in turn iodinates tyrosine residues of thyroglobulin.

Excretion
Sodium iodide I 131 is excreted in urine and feces. The normal range of urinary excretion is 37% to 75% of the administered dose, varying with the thyroid and renal function of the patient. Fecal excretion is about 10%.

16.1 How Supplied

Each capsule contains 3.70 megabecquerels (100 microCi) at time of calibration. Half of each capsule is white, while the other half is either pink, yellow, orange, grey or green according to the manufactured lot.

• The capsules are packaged in plastic vials containing 5 capsules of the same strength and same color. (NDC 65174-461-05).
• Consult the color-coded decay calendar that is updated in January of each year to help you establish which colored capsules correspond to your prescribed dose: https://www.draximage.com/products/us/draximage-i-131-diagnostic-capsules/ or calculate the correct dosage from the date and time of calibration provided on the container label.
• The calibration date and expiration date are indicated on the vial container label.

16.2 Storage and Handling

Store Sodium Iodide I 131 Capsules Diagnostic between 15 °C and 30 °C (59 °F and 86 °F).

Store and dispose of Sodium Iodide I 131 Capsules Diagnostic in compliance with the appropriate regulations of the government agency authorized to license the use of this radionuclide.

This radiopharmaceutical is approved for use by persons under license by the Nuclear Regulatory Commission or the relevant regulatory authority of an Agreement State.